Does RIBOCICLIB Cause Interstitial lung disease? 121 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 121 reports of Interstitial lung disease have been filed in association with RIBOCICLIB (KISQALI). This represents 0.4% of all adverse event reports for RIBOCICLIB.
121
Reports of Interstitial lung disease with RIBOCICLIB
0.4%
of all RIBOCICLIB reports
24
Deaths
52
Hospitalizations
How Dangerous Is Interstitial lung disease From RIBOCICLIB?
Of the 121 reports, 24 (19.8%) resulted in death, 52 (43.0%) required hospitalization, and 17 (14.0%) were considered life-threatening.
Is Interstitial lung disease Listed in the Official Label?
Yes, Interstitial lung disease is listed as a known adverse reaction in the official FDA drug label for RIBOCICLIB.
What Other Side Effects Does RIBOCICLIB Cause?
Neutropenia (3,585)
Nausea (3,404)
Fatigue (3,327)
Malignant neoplasm progression (2,468)
Death (2,452)
Vomiting (1,953)
Diarrhoea (1,830)
White blood cell count decreased (1,683)
Pain (1,637)
Metastases to bone (1,538)
What Other Drugs Cause Interstitial lung disease?
METHOTREXATE (3,049)
RITUXIMAB (2,458)
PEMBROLIZUMAB (2,113)
PREDNISONE (1,850)
CYCLOPHOSPHAMIDE (1,725)
NIVOLUMAB (1,538)
AMIODARONE (1,421)
DOXORUBICIN (1,352)
ETANERCEPT (1,267)
ADALIMUMAB (1,250)
Which RIBOCICLIB Alternatives Have Lower Interstitial lung disease Risk?
RIBOCICLIB vs RIBOFLAVIN
RIBOCICLIB vs RIBOFLAVIN 5'-PHOSPHATE
RIBOCICLIB vs RIBOFLAVIN 5^-PHOSPHATE
RIBOCICLIB vs RIFABUTIN
RIBOCICLIB vs RIFAMPICIN